[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Ramos-Barbosa S, Guazzelli LS, Severo LC: [Cryptococcal mastitis after corticosteroid therapy]. Rev Soc Bras Med Trop; 2004 Jan-Feb;37(1):65-6
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cryptococcal mastitis after corticosteroid therapy].
  • We emphasized the sarcoid granuloma diagnostic's dilemma an the rare manifestation of cryptococcal infection as mastitis.
  • [MeSH-minor] Diagnosis, Differential. Female. Glucocorticoids / adverse effects. Glucocorticoids / therapeutic use. Humans. Middle Aged. Prednisone / adverse effects. Prednisone / therapeutic use. Sarcoidosis / diagnosis. Sarcoidosis / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15042189.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


2. Alfageme Michavila I, Merino Sánchez M, Pérez Ronchel J, Lara Lara I, Suárez García E, López Garrido J: [Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature]. Arch Bronconeumol; 2004 Jan;40(1):45-9
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature].
  • [Transliterated title] Sarcoidosis tras tratamiento con interferón y ribavirina. Presentación de un caso y revisión de la bibliografía.
  • Treatment of active chronic viral hepatitis type C with interferon alpha has proved effective and therefore its use is being extended to a large number of patients.
  • A 49-year-old man with type C chronic, active hepatitis developed new respiratory symptoms and pulmonary infiltrates with hilar and mediastinal adenopathy after 4 months of treatment with pegylated interferon and ribavirin.
  • The transbronchial biopsy showed multiple sarcoid granulomas.
  • When the patient was diagnosed, he had already taken the total dose of interferon and no specific treatment was started.
  • His hepatitis did not respond to therapy and his viral load and transaminase levels remained high.
  • [MeSH-major] Antiviral Agents / adverse effects. Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Ribavirin / adverse effects. Sarcoidosis, Pulmonary / chemically induced
  • [MeSH-minor] Biopsy, Needle. Humans. Male. Middle Aged. Recombinant Proteins. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14718122.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 29
  •  go-up   go-down


3. Zimmermann-Belsing T, Christensen L, Hansen HS, Kirkegaard J, Blichert-Toft M, Feldt-Rasmussen U: A case of sarcoidosis and sarcoid granuloma, papillary carcinoma, and Graves' disease in the thyroid gland. Thyroid; 2000 Mar;10(3):275-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of sarcoidosis and sarcoid granuloma, papillary carcinoma, and Graves' disease in the thyroid gland.
  • During the next 18 months of antithyroid treatment (thiamazole, Thycapzol) hyperthyroidism was difficult to control, the thyroid gland gradually enlarged, and surgery was recommended.
  • During the 36-month period of antithyroid drug treatment TSH was suppressed (<0.01 mU/L) and T3 often elevated despite high doses of thiamazole.
  • Total thyroidectomy was performed, and histologic examination of the removed thyroid tissue confirmed the diagnosis of Graves' disease and also the presence of sarcoid granuloma and metastatic papillary adenocarcinoma with spread to neck lymph nodes.
  • Four months later, a modified radical neck dissection was performed with removal of neck lymph nodes followed by external radiation therapy (2 Gy x 32 fractions to the neck).
  • [MeSH-major] Carcinoma, Papillary / diagnosis. Granuloma / diagnosis. Graves Disease / diagnosis. Sarcoidosis / diagnosis. Thyroid Diseases / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antithyroid Agents / therapeutic use. Humans. Lymphatic Metastasis. Male. Methimazole / therapeutic use. Thyrotropin / blood. Thyroxine / blood. Triiodothyronine / blood


Advertisement
4. Farr AK, Jabs DA, Green WR: Optic disc sarcoid granuloma. Arch Ophthalmol; 2000 May;118(5):728-9
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic disc sarcoid granuloma.
  • [MeSH-minor] Adult. Conjunctival Diseases / drug therapy. Conjunctival Diseases / pathology. Female. Glucocorticoids / therapeutic use. Granuloma / drug therapy. Granuloma / pathology. Humans. Prednisone / therapeutic use. Visual Acuity

  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10815174.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Glucocorticoids; VB0R961HZT / Prednisone
  •  go-up   go-down


5. Honsová E, Sticová E, Sperl J: [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report]. Cesk Patol; 2007 Jan;43(1):27-30
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
  • The patient developed cutaneous sarcoidosis about 6 months after beginning of the combination therapy.
  • Spontaneous regression of the lesions was noted after discontinuation of the treatment.
  • Interferon-alpha is known to stimulate T helper cells with a TH-1 profile immune response, which is the key immunologic event of a sarcoid granuloma formation.
  • In addition to its antiviral action, ribavirin also enhanced the TH-1 response.
  • Incidence of drug induced sarcoidosis may be underreported, because many symptoms of sarcoidosis mimic the side-effects of interferon as fever, myalgias, arthralgias, fatigue and symptoms of pulmonary diseases.
  • [MeSH-major] Antiviral Agents / adverse effects. Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Ribavirin / adverse effects. Sarcoidosis / chemically induced. Skin Diseases / chemically induced
  • [MeSH-minor] Adult. Drug Therapy, Combination. Female. Humans. Polyethylene Glycols. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17370474.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2b; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


6. Toulemonde A, Quereux G, Dréno B: [Sarcoidosis granuloma on a tattoo induced by interferon alpha]. Ann Dermatol Venereol; 2004 Jan;131(1 Pt 1):49-51
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sarcoidosis granuloma on a tattoo induced by interferon alpha].
  • [Transliterated title] Granulome sarcoïdosique sur tatouage induit par l'interféron alpha.
  • Emergence of sarcoidosis in patients with interferon alpha therapy is much more rare.
  • CASE REPORT: A 54 Year-old woman who had been treated for fifty Months with low dose interferon alpha (Roféron(R), 3 millions units, three times a week) for a melanoma of the scalp (adjuvant therapy), developed labial nodules on a permanent tattoo.
  • The diagnosis of sarcoid granuloma was confirmed by histopathologic analysis.
  • Physical examination revealed dyspnea on exertion with a moderate pulmonary interstitial infiltrate on the CT Scan.
  • The diagnosis of cutaneous and pulmonary sarcoidosis in association with interferon alpha therapy was made.
  • Four Months later, at the end of interferon therapy, the nodules had totally disappeared.
  • Interferon alpha might promote the development of sarcoid granuloma by inducing a switch of cytokine secretion from a Th2 to a Th1 cytokine pattern.
  • It is very important to recognize cutaneous sarcoidosis during interferon alpha treatment because pulmonary sarcoidosis can be confused with common general side effects observed with such treatment.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Granuloma / chemically induced. Interferon-alpha / adverse effects. Lip Diseases / chemically induced. Sarcoidosis / chemically induced. Tattooing
  • [MeSH-minor] Female. Humans. Melanoma / drug therapy. Middle Aged. Recombinant Proteins. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15041843.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


7. Tazi A: [Update on sarcoidosis]. Rev Pneumol Clin; 2005 Jun;61(3):203-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other pathogenic mechanisms involved in the formation of the sarcoid granuloma are becoming more clear and have led to the development of new therapeutic approaches such as anti-TNF currently being evaluated in multicentric trials.
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antimalarials / therapeutic use. Drug Therapy, Combination. Genetic Predisposition to Disease. HLA Antigens / genetics. HLA Antigens / immunology. Humans. Immunosuppressive Agents / therapeutic use. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142194.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antibodies, Monoclonal; 0 / Antimalarials; 0 / HLA Antigens; 0 / Immunosuppressive Agents
  • [Number-of-references] 64
  •  go-up   go-down


8. Milman N, Andersen CB, Baslund B, Loft A, Iversen M: Does tumour necrosis factor-alpha inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas? Clin Respir J; 2007 Dec;1(2):106-13
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does tumour necrosis factor-alpha inhibitor infliximab induce histological resolution of pulmonary sarcoid granulomas?
  • BACKGROUND: Sarcoid granuloma formation involves the orchestration of cytokines and chemokines, which modulate the host's immune response to the antigen stimulus.
  • The release of cytokines enhances expression of the pro-inflammatory cytokine tumour necrosis factor-alpha (TNF), which plays a crucial role in the formation of sarcoid granuloma, being released from T-lymphocytes and alveolar macrophages.
  • MATERIALS AND METHODS: A 44-year-old man with biopsy verified chronic pulmonary sarcoidosis being resistant to treatment with corticosteroids and cell cycle inhibitors.
  • Persisting disease activity was confirmed by declining lung function tests and a positive fluorine-18-fluorodeoxyglucose-positron emission tomography scan.
  • The patient was treated with a single course of infliximab 3-mg/kg body weight; 11 days later, a single lung transplantation was performed.
  • Immunohistological staining with the macrophage marker CD68 was performed on lung tissue and mediastinal lymph node tissue from both the initial diagnostic evaluation (prior to infliximab) as well as from the explanted lung (after infliximab).
  • RESULTS: Biopsy specimens from lung and mediastinal lymph nodes prior to infliximab demonstrated sarcoid granulomas, and staining with CD68 showed dense infiltration by macrophages (epithelioid cells) in the central part of the granulomas.
  • In contrast, biopsies from the explanted lung after infliximab demonstrated acellular sarcoid granulomas with central amorphous masses, and staining with CD68 showed complete absence of macrophages.
  • CONCLUSIONS: In this patient, the TNF inhibitor infliximab appeared to induce resolution of sarcoid granulomas starting with disappearance of macrophages probably caused by cell lysis or apoptosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Granuloma / drug therapy. Granuloma / etiology. Sarcoidosis, Pulmonary / complications. Sarcoidosis, Pulmonary / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Chronic Disease. Fluorodeoxyglucose F18. Humans. Infliximab. Lung / pathology. Lymph Nodes / pathology. Macrophages / drug effects. Macrophages / pathology. Male. Mediastinum. Positron-Emission Tomography. Radiopharmaceuticals. Thorax / radionuclide imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20298289.001).
  • [ISSN] 1752-699X
  • [Journal-full-title] The clinical respiratory journal
  • [ISO-abbreviation] Clin Respir J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Radiopharmaceuticals; 0 / Tumor Necrosis Factor-alpha; 0Z5B2CJX4D / Fluorodeoxyglucose F18; B72HH48FLU / Infliximab
  •  go-up   go-down


9. Menon Y, Cucurull E, Reisin E, Espinoza LR: Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci; 2004 Sep;328(3):173-5
Hazardous Substances Data Bank. RIBAVIRIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha-associated sarcoidosis responsive to infliximab therapy.
  • Sarcoidosis, a multisystem disease characterized by noncaseating granulomas, has been reported to be associated with interferon alpha (IFN-alpha) therapy for hepatitis C infection.
  • INF-alpha is known to stimulate T helper cells with a Th1 profile immune response, which is the key immunologic event of a sarcoid granuloma formation.
  • We report a patient treated with IFN-alpha who developed hypercalcemia and renal insufficiency as presenting clinical manifestation of sarcoidosis.
  • Prednisone therapy was effective in controlling hypercalcemia but had to be discontinued due to an increase in hepatitis C viral RNA count.
  • Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha was used as therapy in our patient for its known potent anti-inflammatory effects.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Ribavirin / adverse effects. Sarcoidosis / chemically induced. Sarcoidosis / drug therapy
  • [MeSH-minor] Gastrointestinal Agents / therapeutic use. Humans. Infliximab. Male. Middle Aged. Recombinant Proteins

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15367877.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b; B72HH48FLU / Infliximab
  •  go-up   go-down


10. Torralba KD, Quismorio FP Jr: Sarcoid arthritis: a review of clinical features, pathology and therapy. Sarcoidosis Vasc Diffuse Lung Dis; 2003 Jun;20(2):95-103
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoid arthritis: a review of clinical features, pathology and therapy.
  • The rheumatic manifestations of sarcoidosis include inflammatory arthritis, periarticular soft tissue swelling, tenosynovitis, dactylitis, bone involvement and myopathy.
  • Two types of arthritis that differ in clinical course and prognosis are recognized.
  • Acute sarcoid arthritis is self-limiting and resolves without permanent sequelae.
  • Chronic sarcoid arthritis although less common can progress to cause joint deformities.
  • There are proliferative and inflammatory changes in the synovium and non-caseating granulomas are seen in half of patients.
  • The pathogenesis of sarcoid arthritis is not well understood, however genetic and environmental factors are important.
  • Drug therapy of sarcoid arthritis with nonsteroidal anti-inflammatory agents, corticosteroids, colchicine, antimalarials and/or immunosuppressive medications is based mainly on open label uncontrolled studies.
  • This review focuses on the current knowledge on the various features of sarcoid arthritis including clinical presentation, course, imaging, and pathology.
  • Recent developments in the usage of anti-tumor necrosis factor therapy for sarcoidosis will be reviewed.

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Sarcoidosis Vasc Diffuse Lung Dis. 2004 Mar;21(1):77 [15127979.001]
  • (PMID = 12870718.001).
  • [ISSN] 1124-0490
  • [Journal-full-title] Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
  • [ISO-abbreviation] Sarcoidosis Vasc Diffuse Lung Dis
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunosuppressive Agents; 0 / Tumor Necrosis Factor-alpha; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 97
  •  go-up   go-down


11. Thumfart J, Müller D, Rudolph B, Zimmering M, Querfeld U, Haffner D: Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. Am J Kidney Dis; 2005 Feb;45(2):411-4
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy.
  • We report the case of a 13-year-old boy presenting with severe arterial hypertension and acute renal failure caused by an isolated sarcoid granulomatous interstitial nephritis (GIN).
  • Other known causes of GIN, eg, drug intake or fungal or mycobacterial infection, were excluded, and there was no evidence of extrarenal sarcoid involvement.
  • Renal function improved initially with prednisone treatment.
  • Monthly treatment with infliximab, a tumor necrosis factor-alpha antibody, was started, resulting in steady improvement in renal function and resolution of renal granulomata.
  • In addition, antihypertensive medication could be reduced, and low-dose prednisone therapy was maintained.
  • To our knowledge, this is the first report of successful treatment with infliximab of a patient with sarcoid GIN.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Granuloma / drug therapy. Kidney Diseases / drug therapy. Nephritis, Interstitial / drug therapy. Sarcoidosis / drug therapy

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685521.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; B72HH48FLU / Infliximab
  •  go-up   go-down


12. Oliver SJ, Kikuchi T, Krueger JG, Kaplan G: Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol; 2002 Mar;102(3):225-36
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement.
  • Sarcoidosis, a chronic granulomatous disease of unknown etiology, is treated with immune suppressive drugs such as corticosteroids.
  • Sarcoidosis patients have been reported to benefit clinically from treatment with thalidomide.
  • We administered thalidomide for 16 weeks to eight patients with chronic skin sarcoidosis and evaluated the drug's effects before and with treatment.
  • After thalidomide treatment, all skin biopsies showed decreases in granuloma size and reduction in epidermal thickness.
  • We also observed extensive T cell recruitment into the granulomas, the appearance of multinucleated giant cells, and increased numbers of dermal Langerhans cells (CD1a(+)) and mature dendritic cells (CD83(+) or DC-LAMP(+)).
  • Plasma IL-12 levels increased and remained elevated during the treatment period.
  • Our data suggest that thalidomide treatment of sarcoidosis results in granuloma differentiation to a Th1-type cellular immune response usually associated with protective immunity to tuberculosis and tuberculoid leprosy.
  • [MeSH-major] Dermatologic Agents / immunology. Dermatologic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use. Sarcoidosis / drug therapy. Skin Diseases / drug therapy. Thalidomide / immunology. Thalidomide / therapeutic use
  • [MeSH-minor] Adult. Antigens, CD / drug effects. Dendritic Cells / drug effects. Female. Flow Cytometry. HLA-DR Antigens / drug effects. Humans. Immunohistochemistry. Interleukin-12 / blood. Interleukin-2 / blood. Langerhans Cells / drug effects. Male. Middle Aged. T-Lymphocytes / drug effects. Treatment Outcome. Tumor Necrosis Factor-alpha / drug effects

  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11890709.001).
  • [ISSN] 1521-6616
  • [Journal-full-title] Clinical immunology (Orlando, Fla.)
  • [ISO-abbreviation] Clin. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI22616; United States / NIAMS NIH HHS / AR / AR02187; United States / NCRR NIH HHS / RR / M01-RR00102
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Dermatologic Agents; 0 / HLA-DR Antigens; 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


13. Umezu H, Chida M, Inoue T, Araki O, Tamura M, Tatewaki M, Fukushima Y, Honma K: Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease. Gen Thorac Cardiovasc Surg; 2010 Aug;58(8):434-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoidosis development during induction chemotherapy for lung cancer mimicked progressive disease.
  • We report a rare case of sarcoidosis that developed during induction chemotherapy for primary lung cancer, mimicking progressive disease.
  • Thus, we gave induction chemotherapy consisting of paclitaxel (days 1, 8) + carboplatin (days 1, 8) for two cycles under clinical staging of T2N2M0.
  • After induction chemotherapy, (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) showed positive accumulation of FDG in mediastinal and bilateral hilar lymph nodes that had been negative in a previous FDG-PET examination, which led us to suspect disease progression.
  • Transbronchial lymph node biopsy results showed sarcoid granulomas in the specimens.
  • Following complete resection of the lung cancer, sarcoid granulomas were revealed in both nonneoplastic lung tissue and lymph nodes, which resulted in a diagnosis of lung cancer accompanied with sarcoidosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Sarcoidosis, Pulmonary / chemically induced
  • [MeSH-minor] Biopsy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Disease Progression. Fluorodeoxyglucose F18. Humans. Lymph Node Excision. Lymph Nodes / diagnostic imaging. Lymph Nodes / surgery. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Pneumonectomy. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 1998 Jan-Feb;5(1):177-80 [9458317.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):90-5 [17272320.001]
  • [Cites] Scand J Respir Dis. 1975 May;56(1):20-7 [1145149.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Apr;53(4):196-8 [15875553.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Dec;128(6):892-9 [15573074.001]
  • [Cites] Jpn J Clin Oncol. 1996 Feb;26(1):18-23 [8551662.001]
  • [Cites] Respiration. 1993;60(2):133-6 [8341856.001]
  • [Cites] Intern Med. 2008;47(11):1021-5 [18520114.001]
  • [Cites] Chest. 2007 Apr;131(4):1019-27 [17426205.001]
  • (PMID = 20703868.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Daïen CI, Monnier A, Claudepierre P, Constantin A, Eschard JP, Houvenagel E, Samimi M, Pavy S, Pertuiset E, Toussirot E, Combe B, Morel J, Club Rhumatismes et Inflammation (CRI): Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford); 2009 Aug;48(8):883-6
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases.
  • However, several cases of sarcoidosis have been diagnosed during anti-TNF therapy.
  • Here, we report the largest series of sarcoid-like granulomatosis following TNF blocker treatment.
  • METHODS: A call for observations of sarcoid-like granulomatosis following TNF blocker treatment was sent to the members of the French 'Club Rhumatismes et Inflammation'.
  • RESULTS: Observations of 10 patients [seven females; median age 50.5 (range 27-72) years] with sarcoid-like granulomatosis while on anti-TNF treatment were collected: five were treated with etanercept and five with monoclonal antibodies; four patients received TNF blockers for RA and six for SpA.
  • The median delay between drug discontinuation and remission was 6 (range 1-11) months for clinical signs and 6 (range 2-12) months for biological and radiographic findings.
  • Improvement was observed in all patients after drug discontinuation with or without steroids.
  • CONCLUSIONS: Sarcoid-like granulomatosis is rare but not exceptional in patients treated with TNF blockers (approximately 1/2800) and does not seem to be related to gender, rheumatic disease or in our series the type of anti-TNF drug used (monoclonal antibodies or soluble receptor).
  • [MeSH-major] Antirheumatic Agents / adverse effects. Immunosuppressive Agents / adverse effects. Rheumatic Diseases / drug therapy. Sarcoidosis / chemically induced. Skin Diseases / chemically induced
  • [MeSH-minor] Adalimumab. Adult. Aged. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Etanercept. Female. Granuloma / chemically induced. Humans. Immunoglobulin G / adverse effects. Immunoglobulin G / therapeutic use. Infliximab. Male. Middle Aged. Receptors, Tumor Necrosis Factor / therapeutic use. Sarcoidosis, Pulmonary / chemically induced

  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rheumatology (Oxford). 2010 May;49(5):1019-21; author reply 1021-2 [20056768.001]
  • [CommentIn] Rheumatology (Oxford). 2009 Aug;48(8):865-6 [19403738.001]
  • (PMID = 19423648.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  • [Number-of-references] 41
  •  go-up   go-down


15. Ohno S, Takemasa A, Kawaguchi K, Teruuchi S, Saitoh N, Hasegawa T, Yamaguchi T, Sohara Y, Hironaka M, Sugiyama Y: [Induction chemotherapy (cisplatin + vinorelbine) is found to be markedly effective for squamous cell lung carcinoma with sarcoidosis--a case report]. Gan To Kagaku Ryoho; 2001 Feb;28(2):235-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy (cisplatin + vinorelbine) is found to be markedly effective for squamous cell lung carcinoma with sarcoidosis--a case report].
  • He was treated with an induction chemotherapy (cisplatin 80 mg/m2 + vinorelbine 20 mg/m2) followed by right middle and lower lobectomy with a mediastinal nodal dissection, because the stage of his carcinoma was cT2N2M0.
  • Resected lung tissue showed the disappearance of cancer cells.
  • Dissected mediastinal and hilar lymph nodes showed many sarcoid granulomas.
  • Cisplatin combined with vinorelbine might be an effective chemotherapy for non-small cell lung carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Sarcoidosis / complications. Vinblastine / analogs & derivatives
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242653.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


16. Fernández-Casado A, Martin-Ezquerra G, Yébenes M, Plana F, Elvira-Betanzos JJ, Herrero-González JE, Mariñoso ML, Pujol RM: Progressive supravenous granulomatous nodular eruption in a human immunodeficiency virus-positive intravenous drug user treated with highly active antiretroviral therapy. Br J Dermatol; 2008 Jan;158(1):145-9
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive supravenous granulomatous nodular eruption in a human immunodeficiency virus-positive intravenous drug user treated with highly active antiretroviral therapy.
  • We describe a 41-year-old human immunodeficiency virus-infected woman with a previous history of intravenous drug abuse, who developed multiple linear nodules following the superficial veins on both arms.
  • Histopathological examination disclosed a dermal histiocytic inflammatory reaction with sarcoid-like granuloma formation occasionally showing an intracytoplasmic refractile material in the histiocytic cells.
  • Nodular lesions developed progressively after starting on highly active antiretroviral therapy (HAART) which increased her CD4 cell count and suppressed her viral load.
  • [MeSH-major] Granuloma, Foreign-Body / pathology. HIV Infections / drug therapy. Immune Reconstitution Inflammatory Syndrome / pathology. Skin Diseases / pathology. Substance Abuse, Intravenous / complications
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / adverse effects. Disease Progression. Female. Humans


17. Asakawa H, Tsuji M, Tokumine Y, Kashihara T, Okuno M, Takenaka R, Kawakami F: Gastric T-cell lymphoma presenting with epithelioid granulomas mimicking tuberculosis in regional lymph nodes. J Gastroenterol; 2001 Mar;36(3):190-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric T-cell lymphoma presenting with epithelioid granulomas mimicking tuberculosis in regional lymph nodes.
  • In patients with malignant lymphomas, a sarcoid reaction is occasionally observed.
  • However, lymphoma-related granulomas with caseous necrosis are rare.
  • The sections revealed effacement of the normal architecture and replacement by numerous epithelioid granulomas accompanied by Langhan's type giant cells with or without central caseous necrosis, strongly suggesting tuberculosis.
  • After chemotherapy, a total gastrectomy was performed.
  • The diagnosis of gastric T-cell lymphoma with a sarcoid reaction was confirmed by histological findings of the sections.
  • Namely, the gastric wall was replaced by atypical lymphocytes showing the phenotype of helper T cells, admixed with epithelioid granulomas with Langhan's type giant cells.
  • Thus, this case suggests that regional lymph nodes in gastric lymphomas may be present as epithelioid granulomas with caseous necrosis, mimicking tuberculosis.
  • [MeSH-major] Granuloma, Giant Cell / etiology. Lymphoma, T-Cell / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antitubercular Agents / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Diagnosis, Differential. Gastrectomy. Giant Cells, Langhans. Humans. Male. Middle Aged. Tuberculosis, Lymph Node / diagnosis. Tuberculosis, Lymph Node / drug therapy

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11291883.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


18. Parra ER, Canzian M, Saber AM, Coêlho RS, Rodrigues FG, Kairalla RA, de Carvalho CR, Capelozzi VL: Pulmonary and mediastinal "sarcoidosis" following surgical resection of cancer. Pathol Res Pract; 2004;200(10):701-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous reports indicate that enlarged hilar and mediastinal lymph nodes caused by sarcoid-like reactions may develop after curative resection of cancer, and their presence does not necessarily denote neoplastic recurrence.
  • In this study, we describe two patients who had resected lung and gastric cancer and who later developed pulmonary interstitial infiltrate, concurrent with progressive mediastinal lymphadenopathy initially thought to be caused by intrathoracic dissemination of their cancer.
  • Thus, it is important to recognize this clinical pattern when pulmonary infiltrates develop after complete treatment of cancer in an otherwise relapse-free patient and to encourage lung or lymph node biopsy in these particular settings in order to confirm a sarcoid-like reaction, thereby avoiding unnecessary chemotherapy for presumed tumor recurrence.
  • [MeSH-minor] Aged. Diagnosis, Differential. Digestive System Surgical Procedures. Female. Granuloma / pathology. Humans. Lymph Nodes / pathology. Male. Middle Aged. Thoracic Surgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15648607.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Moin M, Kersten RC, Bernardini F, Kulwin DR: Destructive eyelid lesions in sarcoidosis. Ophthal Plast Reconstr Surg; 2001 Mar;17(2):123-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Bilateral destructive lower eyelid lesions and cicatricial entropion developed in a 43-year-old man with systemic sarcoidosis.
  • Histopathology was consistent with sarcoid granulomas.
  • [MeSH-minor] Adult. Cicatrix / drug therapy. Cicatrix / etiology. Cicatrix / pathology. Disease Progression. Drug Therapy, Combination. Humans. Immunosuppressive Agents / therapeutic use. Male. Methotrexate / therapeutic use. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ophthal Plast Reconstr Surg. 2002 Jul;18(4):313 [12142769.001]
  • (PMID = 11281585.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


20. Nawras A, Alsolaiman MM, Mehboob S, Bartholomew C, Maliakkal B: Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature. Dig Dis Sci; 2002 Jul;47(7):1627-31
MedlinePlus Health Information. consumer health - Sarcoidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic sarcoidosis presenting as a granulomatous tattoo reaction secondary to interferon-alpha treatment for chronic hepatitis C and review of the literature.
  • Interferon-alpha therapy and hepatitis C infection have been implicated in the development of a variety of autoimmune diseases.
  • However, despite the wide use of IFN-alpha therapy for hepatitis C, only a few cases of sarcoidosis have been reported in this context.
  • We report the case of a 42-year-old white female with hepatitis C, who developed systemic sarcoidosis shortly after therapy with IFN-alpha2b.
  • The disease was heralded by the appearance of a cutaneous sarcoid/ foreign body granulomatous reaction at the site of an old tattoo.
  • The sarcoidosis responded to a short course of oral prednisone therapy.
  • [MeSH-major] Antiviral Agents / adverse effects. Granuloma / immunology. Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Sarcoidosis / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Dermatol. 1986 Oct-Dec;4(4):35-45 [3542172.001]
  • [Cites] N Engl J Med. 1989 Nov 30;321(22):1501-6 [2509916.001]
  • [Cites] Rheum Dis Clin North Am. 1998 May;24(2):353-74 [9606763.001]
  • [Cites] Lancet. 1969 Jul 5;2(7610):27-8 [4182795.001]
  • [Cites] J Am Acad Dermatol. 1987 Mar;16(3 Pt 1):534-40 [3819097.001]
  • [Cites] Hautarzt. 1997 Jul;48(7):482-7 [9333628.001]
  • [Cites] J Hepatol. 1998 Jun;28(6):1058-63 [9672184.001]
  • [Cites] Intern Med. 1996 May;35(5):376-9 [8797050.001]
  • [Cites] Clin Exp Dermatol. 1976 Dec;1(4):395-9 [1000880.001]
  • [Cites] Am Rev Respir Dis. 1974 Dec;110(6):774-802 [4611293.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Jun-Jul;24(6-7):679 [10962394.001]
  • [Cites] Intern Med. 1996 Jan;35(1):19-23 [8652926.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1994 Oct;32(10):996-1000 [7844919.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Mar;24(3):364-6 [10804348.001]
  • [Cites] JAMA. 1986 Apr 11;255(14):1878-9 [3951108.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):112S-121S [9305675.001]
  • [Cites] Br J Dermatol. 1999 Feb;140(2):370-2 [10233247.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4952-60 [8648147.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 Nov;10 (11):933-9 [9872615.001]
  • (PMID = 12141827.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha
  • [Number-of-references] 21
  •  go-up   go-down


21. Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS: Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin Sci (Lond); 2007 Mar;112(5):281-9
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Steroid-resistant sarcoidosis has conventionally been treated with various drugs, including methotrexate, azathioprine, cyclophosphamide, cyclosporine, antimalarial drugs and thalidomide, with variable success.
  • Several lines of evidence suggest a critical role of TNF-alpha (tumour necrosis factor-alpha) in the initiation and organization of sarcoid granulomas.
  • Inhibition of TNF-alpha with monoclonal antibodies has therefore received attention as a potential treatment option in therapy-resistant sarcoidosis.
  • A number of case reports and small case series describe successful treatment of refractory disease with infliximab.
  • Pending publication of the RCTs, the use of TNF-alpha blockade in sarcoidosis should remain in the realm of experimental treatment.
  • [MeSH-major] Immunologic Factors / therapeutic use. Sarcoidosis / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adalimumab. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Drug Resistance. Etanercept. Glucocorticoids / therapeutic use. Humans. Immunoglobulin G / therapeutic use. Infliximab. Opportunistic Infections / chemically induced. Receptors, Tumor Necrosis Factor / therapeutic use

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. Infliximab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261090.001).
  • [ISSN] 1470-8736
  • [Journal-full-title] Clinical science (London, England : 1979)
  • [ISO-abbreviation] Clin. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Glucocorticoids; 0 / Immunoglobulin G; 0 / Immunologic Factors; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  • [Number-of-references] 74
  •  go-up   go-down


22. Usuki K, Hamada H, Terasaki Y, Hiwatashi S, Hisadome H, Setoyama M, Kanzaki T, Mera S: Sarcoidosis associated with psoriasis vulgaris. J Dermatol; 2001 Feb;28(2):86-90
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral corticosteroid for the sarcoid lesions and oral PUVA for psoriasis were employed.
  • The cutaneous lesion disappeared within two months after starting the therapy.
  • [MeSH-major] Granuloma, Giant Cell / diagnosis. Psoriasis / diagnosis. Sarcoidosis, Pulmonary / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Eyelids. Glucocorticoids / therapeutic use. Humans. Male. PUVA Therapy. Prednisolone / therapeutic use. Skin Diseases / complications. Skin Diseases / diagnosis. Skin Diseases / drug therapy. Skin Diseases / pathology

  • Genetic Alliance. consumer health - Psoriasis.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11320712.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glucocorticoids; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


23. Suárez-García C, Pérez-Gil A, Pereira-Gallardo S, Codes-Villena M, García-Escudero A, Miguel Camacho F: Interferon-induced cutaneous sarcoidosis in melanoma. Melanoma Res; 2009 Dec;19(6):391-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interferon-induced cutaneous sarcoidosis in the adjuvant treatment of melanoma is a rare side effect.
  • We present the case of a patient who developed two histologically confirmed subcutaneous sarcoid nodules 15 months after starting adjuvant therapy with interferon for lymph node metastatic melanoma in which the primary tumor was not known.
  • This therefore represents the second reported case of interferon-induced cutaneous sarcoidosis in melanoma therapy.
  • As computed axial tomography-PET or other imaging techniques are unable to differentiate between the radiological signs of melanoma metastasis and sarcoidosis, histological evaluation of the granulomatous lesions is essential with a view to avoiding unnecessary treatments.
  • [MeSH-major] Interferon-alpha / adverse effects. Melanoma / drug therapy. Sarcoidosis / chemically induced. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Granuloma. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770687.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


24. Knight AK, Cunningham-Rundles C: Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev; 2006 Feb;5(2):156-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common conditions are idiopathic thrombocytopenia purpura, autoimmune hemolytic anemia, sarcoid-like granulomatous disease and gastrointestinal inflammation.
  • [MeSH-minor] Adult. Anemia, Hemolytic, Autoimmune / drug therapy. Anemia, Hemolytic, Autoimmune / etiology. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Female. Granuloma / drug therapy. Granuloma / etiology. Humans. Hydroxychloroquine / therapeutic use. Immunoglobulins, Intravenous / therapeutic use. Immunosuppressive Agents / therapeutic use. Inflammatory Bowel Diseases / etiology. Pneumonia / etiology. Purpura, Thrombocytopenic, Idiopathic / etiology. Rituximab. Sinusitis / etiology

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16431351.001).
  • [ISSN] 1568-9972
  • [Journal-full-title] Autoimmunity reviews
  • [ISO-abbreviation] Autoimmun Rev
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulins, Intravenous; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 4QWG6N8QKH / Hydroxychloroquine
  • [Number-of-references] 27
  •  go-up   go-down


25. Fernandes SR, Singsen BH, Hoffman GS: Sarcoidosis and systemic vasculitis. Semin Arthritis Rheum; 2000 Aug;30(1):33-46
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better delineate the clinical spectrum of sarcoid vasculitis and its response to therapy.
  • METHODS: Retrospective analysis and a Medline literature review of sarcoid and concurrent vasculitis from 1966.
  • Biopsies revealed features compatible with the diagnosis of sarcoidosis or necrotizing sarcoid granulomata in either skin, lymph node, lung, synovium, bone, bone marrow, liver, trachea, or sclera.
  • Prior reports of sarcoid and vasculitis included 14 adults, of whom half had predominantly small vessel disease, and half had medium- or large-sized vessel disease.
  • Eight previously reported children included seven with primarily large vessel sarcoid vasculitis.
  • However, relapses occurred when the drug was tapered or withdrawn.
  • Sarcoid vasculitis can mimic hypersensitivity vasculitis, polyarteritis nodosa, microscopic polyangiitis, or Takayasu's arteritis.
  • Corticosteroid and cytotoxic therapy is palliative for all forms of sarcoid vasculitis.
  • However, relapses and morbidity from disease and treatment is common.
  • [MeSH-minor] Adolescent. Adult. African Continental Ancestry Group. Angiography. Child. Child, Preschool. Female. Granuloma / etiology. Granuloma / pathology. Humans. Male. Necrosis. Radiography, Thoracic. Retrospective Studies

  • Genetic Alliance. consumer health - Sarcoidosis.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10966211.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 42
  •  go-up   go-down


26. Garg S, Garg K, Altaf M, Magaldi JA: Refractory vertebral sarcoidosis responding to infliximab. J Clin Rheumatol; 2008 Aug;14(4):238-40
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of refractory sarcoidosis may be challenging for clinicians.
  • Despite treatment with conventional therapy, sarcoidosis may be progressive and debilitating.
  • Previous studies have implicated a role for tumor necrosis factor-alpha in granuloma formation as seen in sarcoidosis.
  • There have been recent case-reports supporting treatment of refractory and multisystem sarcoidosis with such agents.
  • We report a case of sarcoidosis, involving the lung and vertebrae, which was refractory to conventional therapy.
  • Our patient's clinical symptoms and radiologic lesions of vertebral sarcoid dramatically improved after treatment with infliximab.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Sarcoidosis / drug therapy. Spinal Diseases / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Aged. Antirheumatic Agents / therapeutic use. Female. Humans. Infliximab. Treatment Failure

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18766126.001).
  • [ISSN] 1536-7355
  • [Journal-full-title] Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  • [ISO-abbreviation] J Clin Rheumatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


27. Antoniu SA: Targeting the TNF-alpha pathway in sarcoidosis. Expert Opin Ther Targets; 2010 Jan;14(1):21-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The existing conventional therapies are not always able to minimize TNF-alpha-driven inflammation and other approaches should be used.
  • AREAS COVERED IN THIS REVIEW: TNF-alpha roles in sarcoid inflammation and granuloma formation are reviewed based on the literature published in the last two decades and the therapies able to target it specifically or non-specifically in sarcoidosis are discussed.
  • WHAT THE READER WILL GAIN: A better understanding of the pathogenic role of TNF-alpha in sarcoidosis and of the scientific rationale of its therapeutic blockade.
  • TAKE HOME MESSAGE: In some subsets of sarcoidosis with more rapid progession and/or therapeutic refractoriness TNF-alpha plays a more prominent role in disease pathogenesis, and its blockade might represent an appropriate therapeutic approach.
  • [MeSH-major] Sarcoidosis / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors. Tumor Necrosis Factor-alpha / physiology
  • [MeSH-minor] Adalimumab. Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Etanercept. Humans. Immunoglobulin G / therapeutic use. Infliximab. Pentoxifylline / therapeutic use. Receptors, Tumor Necrosis Factor / therapeutic use. Signal Transduction / drug effects. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001207.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept; SD6QCT3TSU / Pentoxifylline
  • [Number-of-references] 66
  •  go-up   go-down


28. Doycheva D, Deuter C, Stuebiger N, Zierhut M: Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol; 2009 May;247(5):675-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Interferon alpha, used in the treatment of different viral, autoimmune and malignant diseases, is known to induce a variety of side effects.
  • Recently, induction of sarcoidosis during interferon therapy has been reported.
  • METHODS: We report on three patients who had developed typical signs of ocular sarcoidosis under treatment with interferon alpha for chronic hepatitis C virus infection.
  • The mean duration of interferon treatment before development of uveitis was 10 months.
  • Clinically, all patients demonstrated granulomatous panuveitis with choroidal granulomas of various sizes.
  • In one case, the uveitis developed together with renal failure, fever and malaise.
  • In another patient, the diagnosis of sarcoid induced uveitis was confirmed by positive chest CT scan.
  • The intraocular inflammation was managed with a reduction of the interferon dosage.
  • The therapy with ribavirin was not changed.
  • [MeSH-major] Antiviral Agents / adverse effects. Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Panuveitis / chemically induced. Sarcoidosis / chemically induced
  • [MeSH-minor] Adult. Aged. Choroid Diseases / chemically induced. Choroid Diseases / diagnosis. Choroid Diseases / drug therapy. Drug Therapy, Combination. Female. Glucocorticoids / therapeutic use. Granuloma / chemically induced. Granuloma / diagnosis. Granuloma / drug therapy. Humans. Male. Middle Aged. Polyethylene Glycols. Recombinant Proteins. Retrospective Studies. Ribavirin / adverse effects. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2002 Sep;35(3):282-4 [12192210.001]
  • [Cites] Respirology. 2005 Sep;10 (4):529-34 [16135180.001]
  • [Cites] J Gastroenterol. 2004 Nov;39(11):1106-9 [15580406.001]
  • [Cites] Cancer Treat Rep. 1984 May;68(5):723-6 [6722830.001]
  • [Cites] Curr Opin Pulm Med. 2004 Sep;10(5):435-40 [15316444.001]
  • [Cites] Arch Ophthalmol. 1993 Mar;111(3):350-6 [8447745.001]
  • [Cites] J Gen Virol. 2008 Jan;89(Pt 1):1-47 [18089727.001]
  • [Cites] Allergy. 2006 Aug;61(8):912-20 [16867042.001]
  • [Cites] Medicine (Baltimore). 2005 Mar;84(2):69-80 [15758836.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Jun-Sep;12 (2-3):143-56 [11325598.001]
  • [Cites] Intern Med J. 2008 Mar;38(3):207-10 [18290816.001]
  • [Cites] Acta Haematol. 2004;112(4):217-8 [15564735.001]
  • [Cites] Arch Ophthalmol. 1996 Jun;114(6):726-30 [8639086.001]
  • [Cites] J Immunol. 1996 Jul 15;157(2):522-8 [8752897.001]
  • [Cites] Neurology. 1993 Apr;43(4):662-7 [8469319.001]
  • [Cites] Adv Exp Med Biol. 2003;528:525-8 [12918756.001]
  • [Cites] Cancer Pract. 1995 May-Jun;3(3):164-72 [7599673.001]
  • [Cites] Eur J Immunol. 1996 Mar;26(3):697-703 [8605940.001]
  • [Cites] Int J Clin Pract. 2006 Feb;60(2):201-11 [16451294.001]
  • [Cites] Cancer. 1990 May 15;65(10 ):2237-42 [2346907.001]
  • [Cites] J Immunol. 1998 Apr 1;160(7):3487-93 [9531310.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2007 Jan;48(1):368-75 [17197556.001]
  • [Cites] Eur Radiol. 2004 Sep;14 (9):1716-7 [14740162.001]
  • [Cites] Gastroenterol Clin Biol. 2000 Mar;24(3):364-6 [10804348.001]
  • [Cites] Acta Haematol. 2002;107(3):133-44 [11978934.001]
  • [Cites] Biochem Pharmacol. 1990 Oct 1;40(7):1433-9 [2121146.001]
  • [Cites] J Immunol. 1998 Dec 15;161(12):6567-74 [9862683.001]
  • [Cites] JAMA. 1991 Sep 11;266(10):1375-83 [1715409.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):896-900 [3815268.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12 ):1692-5 [16673135.001]
  • [Cites] Clin Cardiol. 2001 Apr;24(4):286-90 [11303695.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):59-71 [11846976.001]
  • [Cites] Klin Monbl Augenheilkd. 2001 Dec;218(12 ):768-73 [11805868.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1536-7 [1893353.001]
  • [Cites] Am J Surg Pathol. 2005 Jul;29(7):976-9 [15958865.001]
  • [Cites] Br J Ophthalmol. 2003 Feb;87(2):247-8 [12543766.001]
  • [Cites] Br J Ophthalmol. 2007 Mar;91(3):335-9 [17050581.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):2011-8 [9712074.001]
  • [Cites] J Hepatol. 1996 Jan;24(1):38-47 [8834023.001]
  • [Cites] J Hepatol. 1999 Mar;30(3):376-82 [10190717.001]
  • [Cites] Br J Ophthalmol. 1998 Mar;82(3):323-5 [9602634.001]
  • [Cites] Nature. 1978 Jun 29;273(5665):759-61 [566386.001]
  • [Cites] Oncologist. 2001;6(1):34-55 [11161227.001]
  • (PMID = 19034483.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Glucocorticoids; 0 / Interferon-alpha; 0 / Recombinant Proteins; 30IQX730WE / Polyethylene Glycols; 43K1W2T1M6 / interferon alfa-2b; 49717AWG6K / Ribavirin; G8RGG88B68 / peginterferon alfa-2b
  •  go-up   go-down


29. Prasse A, Zissel G, Lützen N, Schupp J, Schmiedlin R, Gonzalez-Rey E, Rensing-Ehl A, Bacher G, Cavalli V, Bevec D, Delgado M, Müller-Quernheim J: Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med; 2010 Aug 15;182(4):540-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sarcoidosis is characterized by noncaseating epitheloid cell granulomas, where excessive tumor necrosis factor-alpha production by pulmonary macrophages plays a critical role in granuloma formation and disease progression, which may lead to fatal organ dysfunction.
  • Sarcoid alveolitis was used as a prototype of immune-mediated chronic lung inflammation.
  • VIP treatment significantly increased the numbers of bronchoalveolar lavage CD4(+)CD127(-)CD25(+) T cells, which showed regulatory activities on conventional effector T cells.
  • In vitro experiments demonstrated the capacity of VIP to convert naive CD4(+)CD25(-) T cells into CD4(+)CD25(+)FoxP3(+) regulatory T cells, suggesting the generation of peripheral regulatory T cells by VIP treatment.
  • CONCLUSIONS: This study is the first to show the immunoregulatory effect of VIP in humans, and supports the notion of inhaled VIP as an attractive future therapy to dampen exaggerated immune responses in lung disorders.
  • Thus, the inhalation of neuropeptides may be developed into a new therapeutic principle for chronic inflammatory lung disorders in humans.
  • [MeSH-major] Sarcoidosis, Pulmonary / drug therapy. Sarcoidosis, Pulmonary / immunology. Vasoactive Intestinal Peptide / immunology. Vasoactive Intestinal Peptide / pharmacology. Vasodilator Agents / immunology. Vasodilator Agents / pharmacology
  • [MeSH-minor] Administration, Inhalation. Bronchoalveolar Lavage Fluid / immunology. Cells, Cultured. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry / methods. Follow-Up Studies. Humans. Male. Middle Aged. T-Lymphocytes, Regulatory / drug effects. T-Lymphocytes, Regulatory / immunology. Tumor Necrosis Factor-alpha / drug effects. Tumor Necrosis Factor-alpha / immunology

  • Genetic Alliance. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442436.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 0 / Vasodilator Agents; 37221-79-7 / Vasoactive Intestinal Peptide
  •  go-up   go-down


30. Gitlin N: Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases. Eur J Gastroenterol Hepatol; 2002 Aug;14(8):883-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases.
  • Neither patient responded to therapy.
  • Both patients developed painless skin nodules, the histology of which was compatible with sarcoidosis.
  • During therapy, both patients also had an elevation of angiotensin converting enzyme (ACE) levels.
  • ACE levels reverted to normal and the skin lesions resolved a few months after cessation of interferon/ribavirin therapy.
  • A repeat liver biopsy in one patient at the end of therapy revealed multiple hepatic granulomas (which were not evident on biopsy before therapy).
  • In conclusion, interferon/ribavirin therapy can evoke a sarcoid-like response, with skin lesions, hepatic granuloma, and elevation of ACE levels.
  • [MeSH-major] Hepatitis C, Chronic / drug therapy. Interferon-alpha / adverse effects. Ribavirin / adverse effects. Sarcoidosis / chemically induced. Skin Diseases / chemically induced

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172411.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 49717AWG6K / Ribavirin; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


31. Koczman JJ, Rouleau J, Gaunt M, Kardon RH, Wall M, Lee AG: Neuro-ophthalmic sarcoidosis: the University of Iowa experience. Semin Ophthalmol; 2008 May-Jun;23(3):157-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5) neuroimaging studies (e.g., cranial magnetic resonance imaging and computed tomography scans);.
  • 7) sarcoid related testing (serum angiotensin converting enzyme, chest radiograph, chest computed tomography scans, Gallium scan, bronchoalveolar lavage, pulmonary function testing);.
  • 8) treatment; and 9) course of disease.
  • The average age at diagnosis was 43.1 years with a standard deviation of 14.1 and a range of 22 to 80 years.
  • Of the 14 patients presenting with optic neuropathy, 8 had optic disc edema, 5 had optic disc pallor and 1 had an optic disc granuloma.
  • All 20 patients were treated with corticosteroids but five required additional immunosuppressive therapy to control disease activity.
  • After treatment of patients with optic neuropathy, visual acuity at last follow-up visit was improved in 5, worsened in 5, and stable (i.e., within one Snellen acuity line of baseline) in 4.
  • CONCLUSION: In our Midwest retrospective case series of biopsy proven neuro-ophthalmic sarcoidosis, patients were predominately white females with a wide age range.
  • Serum angiotensin converting enzyme and chest radiography had relatively poor sensitivity for detecting biopsy proven disease in our study and therefore additional testing for tissue diagnosis might still be necessary for extrapulmonary neuro-ophthalmic sarcoidosis.
  • Corticosteroids are the mainstay of therapy but some patients may require additional immunosuppressive therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glucocorticoids / therapeutic use. Humans. Incidence. Iowa / epidemiology. Magnetic Resonance Imaging. Male. Middle Aged. Papilledema / complications. Papilledema / diagnosis. Papilledema / drug therapy. Retrospective Studies. Tomography, X-Ray Computed. Vision Disorders / complications. Vision Disorders / diagnosis. Vision Disorders / drug therapy

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432542.001).
  • [ISSN] 0882-0538
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


32. Kudrin A, Chilvers ER, Ginawi A, Hazleman BL, Griffiths MH, Thiru S, Ostor AJ: Sarcoid-like granulomatous disease following etanercept treatment for RA. J Rheumatol; 2007 Mar;34(3):648-9
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoid-like granulomatous disease following etanercept treatment for RA.
  • [MeSH-major] Granuloma / chemically induced. Immunoglobulin G / adverse effects. Immunosuppressive Agents / adverse effects. Parotid Gland / pathology
  • [MeSH-minor] Arthritis, Rheumatoid / drug therapy. Bronchi / pathology. Etanercept. Female. Humans. Lymphatic Diseases / chemically induced. Lymphatic Diseases / pathology. Lymphatic Diseases / radiography. Middle Aged. Receptors, Tumor Necrosis Factor / therapeutic use. Sarcoidosis / chemically induced. Sarcoidosis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343313.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


33. Massara A, Cavazzini L, La Corte R, Trotta F: Comment on: Sarcoid-like granulomatosis in patients treated with tumour necrosis factor blockers: 10 cases. Rheumatology (Oxford); 2010 May;49(5):1019-21; author reply 1021-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comment on: Sarcoid-like granulomatosis in patients treated with tumour necrosis factor blockers: 10 cases.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antirheumatic Agents / adverse effects. Granuloma / chemically induced. Receptors, Tumor Necrosis Factor / therapeutic use. Rheumatic Diseases / drug therapy. Sarcoidosis, Pulmonary / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Rheumatology (Oxford). 2009 Aug;48(8):883-6 [19423648.001]
  • (PMID = 20056768.001).
  • [ISSN] 1462-0332
  • [Journal-full-title] Rheumatology (Oxford, England)
  • [ISO-abbreviation] Rheumatology (Oxford)
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Receptors, Tumor Necrosis Factor
  •  go-up   go-down






Advertisement